TR201819564T4 - Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. - Google Patents

Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.

Info

Publication number
TR201819564T4
TR201819564T4 TR2018/19564T TR201819564T TR201819564T4 TR 201819564 T4 TR201819564 T4 TR 201819564T4 TR 2018/19564 T TR2018/19564 T TR 2018/19564T TR 201819564 T TR201819564 T TR 201819564T TR 201819564 T4 TR201819564 T4 TR 201819564T4
Authority
TR
Turkey
Prior art keywords
related disorders
cmt
treatment
novel therapeutic
therapeutic approaches
Prior art date
Application number
TR2018/19564T
Other languages
English (en)
Inventor
Cohen Daniel
Chumakov Ilya
Guerassimenko Oxana
Nabirochkin Serguei
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of TR201819564T4 publication Critical patent/TR201819564T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

Mevcut buluş, Charcot-Marie-Tooth hastalığı ve ilgili bozuklukların tedavisi için bileşimlerle ve yöntemlerle ilgilidir. Daha spesifik olarak, buluş söz konusu hastalığın sujede PMP22 ekspresyonunun azaltılması aracılığıyla tedavi edilmesi için kombine tedavilerle ilgilidir.
TR2018/19564T 2007-11-30 2008-11-28 Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. TR201819564T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03

Publications (1)

Publication Number Publication Date
TR201819564T4 true TR201819564T4 (tr) 2019-01-21

Family

ID=39264515

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/19564T TR201819564T4 (tr) 2007-11-30 2008-11-28 Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.

Country Status (24)

Country Link
US (6) US8992891B2 (tr)
EP (4) EP2065038A1 (tr)
JP (4) JP5953000B2 (tr)
KR (1) KR101546031B1 (tr)
CN (2) CN101883561B (tr)
AU (1) AU2008328745B2 (tr)
BR (1) BRPI0819678A2 (tr)
CA (3) CA3031484C (tr)
CY (2) CY1113980T1 (tr)
DK (2) DK2211846T3 (tr)
EA (3) EA032767B1 (tr)
ES (3) ES2703508T3 (tr)
HR (2) HRP20130345T1 (tr)
HU (1) HUE040596T2 (tr)
IL (1) IL205741A0 (tr)
LT (1) LT2609916T (tr)
MX (1) MX2010005709A (tr)
NZ (1) NZ585440A (tr)
PL (2) PL2211846T3 (tr)
PT (2) PT2211846E (tr)
SI (2) SI2211846T1 (tr)
TR (1) TR201819564T4 (tr)
WO (1) WO2009068668A1 (tr)
ZA (1) ZA201003610B (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
WO2011061304A1 (en) * 2009-11-20 2011-05-26 Pharnext New diagnostic tools for charcot-marie-tooth disease
EP2523661B1 (en) 2010-01-15 2017-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitors for the treatment of autism
WO2012045804A1 (en) * 2010-10-08 2012-04-12 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
RU2013139247A (ru) 2011-02-23 2015-03-27 Церулеус Лтд. Комплексы флумазенила, содержащие их композиции и их применения
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
US10016142B2 (en) 2012-10-19 2018-07-10 Sidewaystrategies Llc Systems and methods for nerve mapping and monitoring
US20150329483A1 (en) * 2012-12-17 2015-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth
SI3003268T1 (sl) 2013-06-05 2019-01-31 Pharnext Stabilne oralne raztopine za kombinirane API
JP6619744B2 (ja) 2014-02-11 2019-12-11 ファーネクストＰｈａｒｎｅｘｔ 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用
CN106456571B (zh) * 2014-02-24 2021-07-27 法奈科斯公司 用于治疗机械性神经元损伤的组合物
US20160339015A1 (en) * 2015-05-20 2016-11-24 Lupin Inc. Oral pharmaceutical composition of methylergonovine
EP3426349A4 (en) 2016-03-09 2020-01-01 Ionis Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US11272871B2 (en) 2016-07-14 2022-03-15 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
CA3044691A1 (en) 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
CA3071114A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
CA3176768A1 (en) * 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
RU2184570C2 (ru) 1997-09-30 2002-07-10 Дайити Фармасьютикал Ко., Лтд. Препараты для орального введения
CA2345642A1 (en) 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
JP2004504002A (ja) * 1999-01-19 2004-02-12 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトシャペロンタンパク質
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
DE60237372D1 (de) * 2001-07-04 2010-09-30 Sun Pharma Advanced Res Co Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
MXPA04008772A (es) * 2002-03-14 2004-12-06 Euro Celtique Sa Composiciones de clorhidrato de naltrexona.
PT1578350E (pt) * 2002-03-26 2009-08-27 Euro Celtique Sa Composições revestidas com geles de libertação constante
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
CA2516816C (en) * 2003-02-24 2012-02-07 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
WO2004091623A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
WO2004091593A2 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
PT1663229E (pt) 2003-09-25 2010-07-13 Euro Celtique Sa CombinaãŽes farmac—uticas de hidrocodona e naltrexona
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2382975A3 (en) * 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
CN105997969B (zh) 2011-03-01 2022-03-25 法耐斯特公司 基于巴氯芬和阿坎酸的神经性障碍疗法
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
SI3003268T1 (sl) 2013-06-05 2019-01-31 Pharnext Stabilne oralne raztopine za kombinirane API
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
US10322101B2 (en) 2019-06-18
SI2211846T1 (sl) 2013-07-31
JP2016145227A (ja) 2016-08-12
CA3031484A1 (en) 2009-06-04
PT2211846E (pt) 2013-05-10
EP2609916B1 (en) 2018-11-07
EA035711B1 (ru) 2020-07-29
US20180250289A1 (en) 2018-09-06
HRP20182147T1 (hr) 2019-03-08
EA201301078A1 (ru) 2014-06-30
CN104257657B (zh) 2017-07-04
JP6608309B2 (ja) 2019-11-20
US20180360785A1 (en) 2018-12-20
ZA201003610B (en) 2011-06-29
ES2831855T3 (es) 2021-06-09
EP3459535B1 (en) 2020-08-12
PL2609916T3 (pl) 2019-03-29
HRP20182147T8 (hr) 2019-04-19
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
EP2211846B1 (en) 2013-02-27
KR20100088160A (ko) 2010-08-06
CN101883561B (zh) 2014-07-30
EA201791669A2 (ru) 2017-12-29
ES2703508T3 (es) 2019-03-11
US20200155491A1 (en) 2020-05-21
EP2065038A1 (en) 2009-06-03
US20180338969A1 (en) 2018-11-29
HRP20130345T1 (hr) 2013-07-31
IL205741A0 (en) 2010-11-30
EA201000914A1 (ru) 2010-12-30
DK2609916T3 (en) 2019-01-21
KR101546031B1 (ko) 2015-08-25
HUE040596T2 (hu) 2019-03-28
BRPI0819678A2 (pt) 2017-05-09
EP3459535A1 (en) 2019-03-27
EA019402B1 (ru) 2014-03-31
US20100310641A1 (en) 2010-12-09
JP2018109043A (ja) 2018-07-12
JP2019142917A (ja) 2019-08-29
PT2609916T (pt) 2019-01-10
CA3031490C (en) 2021-05-04
CA3031490A1 (en) 2009-06-04
DK2211846T3 (da) 2013-04-29
US20150157626A1 (en) 2015-06-11
ES2408785T3 (es) 2013-06-21
LT2609916T (lt) 2019-02-11
CA2705408C (en) 2019-04-23
EA201791669A3 (ru) 2018-03-30
US8992891B2 (en) 2015-03-31
EP2211846A1 (en) 2010-08-04
JP5953000B2 (ja) 2016-07-13
AU2008328745B2 (en) 2014-01-30
CA3031484C (en) 2021-05-04
MX2010005709A (es) 2010-11-05
CY1121183T1 (el) 2020-05-29
EP2609916A1 (en) 2013-07-03
JP2011504915A (ja) 2011-02-17
CN104257657A (zh) 2015-01-07
CY1113980T1 (el) 2016-07-27
CA2705408A1 (en) 2009-06-04
AU2008328745A1 (en) 2009-06-04
WO2009068668A1 (en) 2009-06-04
US10463640B2 (en) 2019-11-05
CN101883561A (zh) 2010-11-10
EA032767B1 (ru) 2019-07-31
NZ585440A (en) 2011-12-22
US10441558B2 (en) 2019-10-15

Similar Documents

Publication Publication Date Title
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
MY161656A (en) Therapeutic use of diaminophenothiazines
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201170349A1 (ru) Модуляторы mif
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
EA201270575A1 (ru) Соединения
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
MY186456A (en) Quinazoline carboxamide azetidines
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
EA201190209A1 (ru) Соединения для лечения метаболических расстройств
EA201190208A1 (ru) Соединения для лечения метаболических расстройств